NIM
ELVN icon

NEOS Investment Management’s Enliven Therapeutics ELVN Stock Holding History

NEOS Investment Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,314
Closed -$825K – 657
2025
Q3 		$825K Buy
40,314
+7,735
+24% +$156K 0.01% 539
2025
Q2 		$654K Buy
32,579
+8,931
+38% +$169K 0.01% 512
2025
Q1 		$465K Buy
+23,648
New +$509K 0.01% 519

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

NEOS Investment Management's ELVN Position: Q4 2025 in Review

NEOS Investment Management sold out of Enliven Therapeutics (ELVN) in Q4 2025, closing a stake of 40,314 shares — an estimated $825K sold.

NEOS Investment Management first reported a position in ELVN in Q1 2025 and held it in 3 quarters. The position peaked at $825K in Q3 2025. 125 funds tracked by Wall St. Rank hold ELVN as of Q4 2025.

  • NEOS Investment Management reported no remaining Enliven Therapeutics position as of Q4 2025 after selling out during the quarter.
  • NEOS Investment Management sold 40,314 Enliven Therapeutics shares in Q4 2025, an estimated $825K.
  • NEOS Investment Management first reported a position in Enliven Therapeutics in Q1 2025 and held it in 3 quarters.
  • NEOS Investment Management's Enliven Therapeutics position peaked at $825K in Q3 2025.
  • 125 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2025.

Based on NEOS Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.